May 21, 2013
The Particulars: Surgery is typically the indicated initial treatment of loco-regional non-small cell lung cancer (NSCLC). Data are lacking on how surgical management of NSCLC varies by race.
Data Breakdown: For a study, 1.2 million patients were assessed following their first course of treatment after an initial NSCLC diagnosis.…
May 17, 2013
PHILADELPHIA — As the multiple disciplines that make up pulmonary, critical care, and sleep medicine gather here, the 2013 American Thoracic Society (ATS) International Conference will have a “big tent” atmosphere devoted to the needs of both clinical medicine and basic science.…
March 7, 2013
Among patients with primary lung cancer undergoing lobectomy, having a higher BMI appears to increase total operating room time. American investigators found that the average operating room time increased by 7.2 minutes for every 10-unit increase in BMI.
Abstract: Annals of Thoracic Surgery, December 2012.…
January 29, 2013
The Particulars: Currently, there is no reliable method for identifying pathologically staged, node-negative non-squamous non-small cell lung cancers (NSCLC) smaller than 2 cm (T1a). As adoption of low-dose CT screening rapidly increases, it is possible that a novel molecular assay may help detect T1a node-negative tumors early.…
Purpose: Size criteria have been used as a gold standard for a long time in cancer staging of all kinds of solid tumors. However, real tumor mass is usually neither spherical nor symmetrical in shape. Therefore, single length (diameter) of tumor does not stand for the tumor volume exactly, because of its asymmetry and irregularity in shape.…
January 28, 2013
Purpose: Trimodality therapy incorporating preoperative chemotherapy (cisplatin-etoposide, CisP/Etop), radiation, and surgery is generally considered the standard of care for Superior Sulcus (SS) cancers. Intergroup SWOG 9416 demonstrated 5-year survival of 44%, with relapse mainly in distant sites. To address this issue, S0220 was designed to substitute single-agent docetaxel (DTX) for CisP/Etop during the consolidation phase after surgery.…
January 9, 2013
Performing routine needle biopsy of suspicious lung nodules in surgical candidates appears to have several benefits, according to Canadian investigators. With routine needle biopsy, 16% of patients avoided operation and only 2.7% underwent resection of a pathologically benign nodule. Sensitivity, specificity, and positive and negative predictive values were 100%, 75%, 99.7%, and 100%, respectively.…
December 19, 2012
Reduces risk of collapsed lung following lung biopsy…
October 22, 2012
Heavy concentrations of secondhand smoke, such as those found in smoke-filled bars and cars, can lead to airway restriction for bystanders within minutes of exposure. The study, presented at CHEST 2012, the annual meeting of the American College of Chest Physicians, showed that after 20 minutes of exposure to highly concentrated secondhand smoke, participants experienced near immediate physiologic changes, including airway resistance and impedance.…
October 12, 2012
Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.…
